SAB Biotherapeutics appoints Samuel J. Reich as Executive Chairman; $350K salary, 350K share option.

SAB Biotherapeutics, Inc.

Reich named Executive Chairman effective Oct 25, 2021; reports to Board of Directors.
Annual base salary of $350,000; eligible for annual cash bonus of at least 50% of base salary.
Granted nonqualified stock option for 350,000 shares vesting over three years (1/3 year 1, remainder monthly).
Severance: 12 months salary + COBRA if terminated without cause/good reason; 24 months if in change of control period.
Agreement includes standard restrictive covenants (non-disclosure, non-compete, non-solicitation).

item 1.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Samuel J. Reich

Executive Chairman of the Board of Directors

SABS · SAB Biotherapeutics, Inc.

Effective: 2021-10-25
Filed: November 19, 2021, 6:59 PM ET

On November 17, 2021, and effective as of October 25, 2021, SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”) entered into an Executive Employment Agreement with Mr. Samuel J. Reich (the “Agreement”) to serve as the Company’s Executive Chairman of the Board of Directors.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Samuel J. Reich was appointed as Executive Chairman of the Board of Directors at SAB Biotherapeutics, Inc..

Action: appointed
Role: Executive Chairman of the Board of Directors

Exact text from the filing

On November 17, 2021, and effective as of October 25, 2021, SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”) entered into an Executive Employment Agreement with Mr. Samuel J. Reich (the “Agreement”) to serve as the Company’s Executive Chairman of the Board of Directors.

View on SEC.gov

SAB Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-21-029397

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.